GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Takeda Pharmaceutical Company (TAK) shares

Learn how to easily invest in Takeda Pharmaceutical Company shares.

Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical Company shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical Company employs 47,099 staff and has a trailing 12-month revenue of around USD$3.3 trillion.

How to buy shares in Takeda Pharmaceutical Company

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TAK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Global markets
Your capital is at risk.
Saxo Markets
Global markets
Your capital is at risk.
CFD Service. Your capital is at risk.
BlackBull Markets
CFD Service. Your capital is at risk.
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
CFD Service. Your capital is at risk.
CFD Service. Your capital is at risk.

Compare up to 4 providers

How has Coronavirus impacted Takeda Pharmaceutical Company's stock price?

Since the stock market crash in March caused by coronavirus, Takeda Pharmaceutical Company's stock price has had significant negative movement.

Its last market close was $14.02, which is 25.39% down on its pre-crash value of $18.79 and 12.79% up on the lowest point reached during the March crash when the stocks fell as low as $12.43.

If you had bought $1,000 worth of Takeda Pharmaceutical Company stocks at the start of February 2020, those stocks would have been worth $689.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $724.13.

Is it a good time to buy Takeda Pharmaceutical Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Takeda Pharmaceutical Company shares at a glance

Information last updated 2021-10-16.
Latest market close$14.02
52-week range$14.02 - $19.97
50-day moving average $16.28
200-day moving average $16.77
Wall St. target price$20.37
PE ratio 11.677
Dividend yield $180 (4.14%)
Earnings per share (TTM) $1.21

Takeda Pharmaceutical Company stock price (NYSE: TAK)

Use our graph to track the performance of TAK stocks over time.

Takeda Pharmaceutical Company price performance over time

Historical closes compared with the close of $14.02 from 2021-10-21

1 week (2021-10-15) -0.57%
1 month (2021-09-23) -18.25%
3 months (2021-07-23) -16.84%
6 months (2021-04-23) -17.82%
1 year (2020-10-23) -15.85%
2 years (2019-10-23) -20.30%
3 years (2018-10-23) 20.07
5 years (2016-10-21) 22.83

Is Takeda Pharmaceutical Company under- or over-valued?

Valuing Takeda Pharmaceutical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Takeda Pharmaceutical Company's P/E ratio

Takeda Pharmaceutical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Takeda Pharmaceutical Company shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Takeda Pharmaceutical Company's PEG ratio

Takeda Pharmaceutical Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1158. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Takeda Pharmaceutical Company's EBITDA

Takeda Pharmaceutical Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1,031.1 billion.

The EBITDA is a measure of a Takeda Pharmaceutical Company's overall financial performance and is widely used to measure a its profitability.

Takeda Pharmaceutical Company financials

Revenue TTM $3,345.6 billion
Operating margin TTM 16.04%
Gross profit TTM $2,203.6 billion
Return on assets TTM 2.65%
Return on equity TTM 8.69%
Profit margin 12.89%
Book value $1,665.55
Market capitalisation $44.5 billion

TTM: trailing 12 months

Shorting Takeda Pharmaceutical Company shares

There are currently 6.5 million Takeda Pharmaceutical Company shares held short by investors – that's known as Takeda Pharmaceutical Company's "short interest". This figure is 12.1% up from 5.8 million last month.

There are a few different ways that this level of interest in shorting Takeda Pharmaceutical Company shares can be evaluated.

Takeda Pharmaceutical Company's "short interest ratio" (SIR)

Takeda Pharmaceutical Company's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical Company shares currently shorted divided by the average quantity of Takeda Pharmaceutical Company shares traded daily (recently around 1.7 million). Takeda Pharmaceutical Company's SIR currently stands at 3.77. In other words for every 100,000 Takeda Pharmaceutical Company shares traded daily on the market, roughly 3770 shares are currently held short.

However Takeda Pharmaceutical Company's short interest can also be evaluated against the total number of Takeda Pharmaceutical Company shares, or, against the total number of tradable Takeda Pharmaceutical Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical Company's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical Company shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical Company shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical Company.

Takeda Pharmaceutical Company share dividends


Dividend payout ratio: 27.87% of net profits

Recently Takeda Pharmaceutical Company has paid out, on average, around 27.87% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.9% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Company shareholders could enjoy a 5.9% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Company's case, that would currently equate to about $180 per share.

While Takeda Pharmaceutical Company's payout ratio might seem fairly standard, it's worth remembering that Takeda Pharmaceutical Company may be investing much of the rest of its net profits in future growth.

Takeda Pharmaceutical Company's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 29 March 2021 (the "ex-dividend date").

Takeda Pharmaceutical Company share price volatility

Over the last 12 months, Takeda Pharmaceutical Company's shares have ranged in value from as little as $14.02 up to $19.97. A popular way to gauge a stock's volatility is its "beta".

TAK.US volatility(beta: 1.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Company's is 1.1019. This would suggest that Takeda Pharmaceutical Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Takeda Pharmaceutical Company overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc. ; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site